What the FDA labels say about taking them together
Elbasvir/grazoprevir and nirmatrelvir/ritonavir
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names elbasvir/grazoprevir in its drug interactions section; the elbasvir/grazoprevir label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Hepatitis C direct acting antivirals elbasvir/grazoprevir ↑ antiviral Increased grazoprevir concentrations can result in alanine transaminase (ALT) elevations. …”
Check it at the source: the elbasvir/grazoprevir FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC); the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the elbasvir/grazoprevir label say about nirmatrelvir/ritonavir?
Elbasvir/grazoprevir's label (effective March 13, 2026) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ZEPATIER), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 164dc02a-9180-426a-b8b5-04ab39d2bbd4), via openFDA; the full label on DailyMed
What does the nirmatrelvir/ritonavir label say about elbasvir/grazoprevir?
Nirmatrelvir/ritonavir label, drug interactionsHepatitis C direct acting antivirals elbasvir/grazoprevir ↑ antiviral Increased grazoprevir concentrations can result in alanine transaminase (ALT) elevations. glecaprevir/pibrentasvir Avoid concomitant use of glecaprevir/pibrentasvir with PAXLOVID. ombitasvir/paritaprevir/ritonavir and dasabuvir Refer to the ombitasvir/paritaprevir/ritonavir and dasabuvir label for further information. sofosbuvir/velpatasvir/voxilaprevir Refer to the sofosbuvir/velpatasvir/voxilaprevir prescribing information for further information.
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elbasvir/grazoprevir | Nirmatrelvir/ritonavir | |
|---|---|---|
| Labeled for | Hepatitis C | COVID-19 |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $49.24 per unit 300-100 mg dose pack |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once